Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
CBG: verhoogd risico op tuberculose bij pralsetinib
jun 2023 | Longoncologie, Tuberculose